CoChat

Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis

Open access
Yang, Yuan, Yang, Howard H., Hu, Ying, Watson, Peter H., Liu, Huaitian, Geiger, Thomas R., Anver, Miriam R., Haines, Diana C., Martin, Philip, Green, Jeffrey E., Lee, Maxwell P., Hunter, Kent W., Wakefield, Lalage M. · 2017 · Oncotarget
Cited by 121

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Yuan Yang 1,* , Howard H. Yang 2,* , Ying Hu 2 , Peter H. Watson 3 , Huaitian Liu 2 , Thomas R. Geiger 1 , Miriam R. Anver 4 , Diana C. Haines 4 , Philip Martin 4 , Jeffrey E. Green 1 , Maxwell P. Lee 2,* , Kent W. Hunter 1,* and Lalage M. Wakefield 1,* 1 Lab of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 2 High Dimension Data Analysis Group, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 3 British Columbia Cancer Agency, Vancouver Island Center, Victoria, British Columbia, Canada 4 Pathology Histotechnology Lab, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick MD, USA * These authors have contributed equally to this work Correspondence to: Lalage M. Wakefield, email: // Keywords : metastasis, breast cancer, immunocompetent mouse models, genomics, experimental therapeutics Received : December 02, 2016 Accepted : February 18, 2017 Published : February 25, 2017 Abstract Effective drug development to combat metastatic disease in breast cancer would be aided by the availability of well-characterized preclinical animal models that (a) metastasize with high efficiency, (b) metastasize in a reasonable time-frame, (c) have an intact immune system, and (d) capture some of the heterogeneity of the human disease. To address these issues, we have assembled a panel of twelve mouse mammary cancer cell lines that can metastasize efficiently on implantation into syngeneic immunocompetent hosts. Genomic characterization shows that more than half of the 30 most commonly mutated genes in human breast cancer are represented within the panel. Transcriptomically, most of the models fall into the luminal A or B intrinsic molecular subtypes, despite the predominance of an aggressive, poorly-differentiated or spindled histopathology in all models. Patterns of immune cell infiltration, proliferation rates, apoptosis and angiogenesis differed significantly among models. Inherent within-model variability of the metastatic phenotype mandates large cohort sizes for intervention studies but may also capture some relevant non-genetic sources of variability. The varied molecular and phenotypic characteristics of this expanded panel of models should aid in model selection for development of antimetastatic therapies in vivo , and serve as a useful platform for predictive biomarker identification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15695

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 121

Metadata

Authors
Yang, Y., Yang, H. H., Hu, Y., Watson, P. H., Liu, H., Geiger, T. R., Anver, M. R., Haines, D. C., Martin, P., Green, J. E., Lee, M. P., Hunter, K. W., & Wakefield, L. M.
Venue
Oncotarget
Published
2017-02-25
Volume
8
Issue
19
Pages
30621-30643
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2590028062
Cited by
121
References
7
FWCI
4.09
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. https://app.cochat.ai/papers/10.18632/oncotarget.15695
The paper
Yang, Y., Yang, H. H., Hu, Y., Watson, P. H., Liu, H., Geiger, T. R., Anver, M. R., Haines, D. C., Martin, P., Green, J. E., Lee, M. P., Hunter, K. W., & Wakefield, L. M. (2017). Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. https://doi.org/10.18632/oncotarget.15695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.